Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

CD40L-augmented autologous tumor infiltrating lymphocytes

A preparation of autologous tumor-infiltrating lymphocytes (TILs) derived from a patient's tumor that have been stimulated ex vivo with CD40 ligand (CD40L, tumor necrosis factor superfamily member 5, TNFSF5, CD154, TNF-related activation protein, TRAP, gp39) during cell expansion, with potential immunomodulating and antineoplastic activities. Upon administration, the CD40L-augmented autologous TILs specifically recognize and kill the patient's tumor cells. Stimulation with a CD40L may enhance both the expansion of the TILs and the tumor-killing ability of the TILs when returned to the patient.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:CD40 ligand-stimulated autologous TILs
CD40L TIL
CD40L-augmented autologous TILs
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search